Lee Chan Henry 4

4 · BeOne Medicines Ltd. · Filed Jun 15, 2026

AI-generated summary of this filing

Updated Jun 15, 2026

BeOne Medicines (ONC) SVP/GC Lee Chan Henry Receives RSUs; Sells Shares

What Happened

Lee Chan Henry, Senior Vice President and General Counsel of BeOne Medicines (ONC), had a small open‑market sale and larger awards recorded on 2026-06-11. He sold 428 American Depositary Shares (ADSs) at $257.63 each for total proceeds of $110,268. At the same time he was granted/received awards totaling 132,379 ADSs (45,071 ADSs reported as one award and 87,308 ADSs reported as a derivative award) valued at $0 on grant (these are restricted share units, not immediate cash purchases).
The RSU awards are subject to vesting; together the 132,379 ADSs equal approximately 1,720,927 ordinary shares on an underlying basis (see footnote on ADS ratio).

Key Details

Transaction date: 2026-06-11; Form 4 filed 2026-06-15.
Sale: 428 ADSs @ $257.63 = $110,268 (footnote F3 indicates this sale was made to satisfy mandatory tax withholding in connection with RSU vesting).
Awards: 45,071 ADSs (footnote F1) and 87,308 ADSs (derivative, footnote F5) granted/awarded at $0 (restricted share units).
ADS conversion: per footnote F2, each ADS represents 13 ordinary shares (so 428 ADSs = 5,564 ordinary shares; 132,379 ADSs ≈ 1,720,927 ordinary shares).
Vesting: RSUs vest over a four‑year schedule (25% on the first anniversary with the balance vesting monthly over the following 36 months per F5; F1/F3 reference similar annual 1/4th vesting and accelerated vesting on certain termination/change‑in‑control events).
Shares owned after transaction: not specified in the provided excerpt.
Filing timeliness: Form filed 6/15/2026 for a 6/11/2026 transaction; the filing shows on its face and does not flag a late filing.

Context

The awards are RSUs (restricted share units), which are grants that convert into shares over time if the executive remains employed or upon certain qualifying events; they are not an immediate purchase signal. The small sale reported here was a tax‑withholding sale related to RSU vesting, per the filing, which is a routine administrative transaction rather than an independent investment decision.

Form 4

Period: 2026-06-11

SVP, General Counsel

Transactions

Award
Ordinary Shares
[F1]
2026-06-11+45,071→ 346,554 total
Sale
American Depositary Shares
[F2][F3]
2026-06-11$257.63/sh−428$110,268→ 0 total
Award
Share Option (Right to Buy)
[F4][F5]
2026-06-11+87,308→ 87,308 total
Exercise: $20.81Exp: 2036-06-10→ Ordinary Shares (87,308 underlying)

Footnotes (5)

[F1]Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 11, 2026, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
[F2]Each American Depositary Share represents 13 Ordinary Shares.
[F3]The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.
[F4]The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
[F5]These securities vest over a four-year period as follows: 25% on the first anniversary of June 11, 2026 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Signature

/s/ Qing Nian, as Attorney-in-Fact|2026-06-15

1 file